Bendamustine is effective in T‐Cell prolymphocytic leukaemia

Herbaux, Charles; Genet, Philippe; Bouabdallah, Krimo; Pignon, Jean‐Michel; Debarri, Houria; Guidez, Stéphanie; Bétrian, Sarah; Leleu, Xavier; Facon, Thierry; Morschhauser, Franck; Damaj, Gandhi; Cazin, Bruno; Ysebaert, Loïc

doi:10.1111/bjh.13175

Cited by 37 publications

(25 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kidney failure was not reported. [21][22][23][24] Bendamustine is effective against indolent lymphomas, 25,26 chronic lymphocytic leukemia, mantle cell lymphoma, 27 large B-cell lymphomas, 28 peripheral T-cell lymphomas, 29,30 HLs [31][32][33] and multiple myelomas. [34][35][36] The doses used are 50-180 mg/m 2 on days 1 and 2 or a total dose of 100-360 mg/m 2 in a single intravenous perfusion over 30-60 min every 21-28 days.…”

Section: Alternatives To Bcnu In Conditioning Regimensmentioning

confidence: 99%

Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review

Damaj

Cornillon

Bouabdallah

et al. 2017

Bone Marrow Transplant

View full text Add to dashboard Cite

High-dose chemotherapy preceding autologous hematopoietic stem cell transplantation (auto-HSCT) is one treatment option for patients with Hodgkin (HL) or non-Hodgkin lymphoma (NHL). The most frequently used intensive chemotherapy is a combination of carmustine (BCNU), etoposide, cytarabine and melphalan (BEAM). However, BCNU is consistently in short supply, and there has been a recent dramatic increase in its cost, necessitating the utilization of conditioning alternatives. The busulfan-based conditioning regimen known as the busulfan-cyclophosphamide-etoposide (BuCyE) combination is the second most-studied conditioning regimen worldwide after BEAM, and it exhibits a benefit/risk ratio that is comparable to that of BEAM. In addition to these two combinations, the present manuscript also summarizes data reported for other conditioning combinations. Owing to the lack of prospective and comparative studies, a comparison of the toxicities and medicoeconomical profiles of these treatments is warranted to identify effective replacements for BCNU-based conditioning.

show abstract

Section: Alternatives To Bcnu In Conditioning Regimensmentioning

confidence: 99%

Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review

Damaj

Cornillon

Bouabdallah

et al. 2017

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Despite responses to chemo/immunotherapy (alemtuzamab 11,12 with/without pentostatin, 13 hematopoietic cell transplantation, 14 fludarabine/mitoxantrone/cyclophosphamide, 15 or methylpredinisolone 16 and other alkylators), 17 the median progression-free survival (8-12 months) and overall survival (20-24 months) in T-PLL remain dismal. 18 Longer survival is seen with hematopoietic cell transplantation; however, 33% to 47% of patients relapse within 36 months and treatment-related mortality is almost as high.…”

Section: Resultsmentioning

confidence: 99%

T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib)

Li¹,

Waite

Wolfson

2017

Blood Advances

View full text Add to dashboard Cite

show abstract

“…There are currently no data using bendamustine as first-line treatment of peripheral T-cell lymphoma (PTCL). Limited data, however, exist in relapsed/refractory PTCL [ Table III ] [ 31 , 32 , 58 ]. Prospective data from a French study included 60 patients with predominantly angio-immunoblastic lymphadenopathy and PTCL not otherwise specified [ 31 ].…”

Section: T-cell Lymphomamentioning

confidence: 99%

“…[ 32 ] Retrospective 20 AILTPTCL-nossALCL, T-PLL, T-LGL, MF, SS 68 73 60-100day 1–2/4 w 55 10 6 PFS44% Herbaux et al . [ 58 ] Retrospective 15 T-PLL 33 62 70–120day 1–2/3 w 53 20 5 AILT, angioimmunoblastic T-cell lymphoma; PTCL-nos, peripheral T-cell lymphoma-not otherwise specified; sALCL, systemic anaplastic large cell lymphoma; T-PLL, T-cell prolymphocytic leukemia; T-LGL, T-large granular lymphocytosis; MF, mycosis fungoides; SS, Sezary Syndrome. …”

Section: T-cell Lymphomamentioning

confidence: 99%

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update

Cheson

Brugger

Damaj

et al. 2015

Leukemia & Lymphoma

Self Cite

View full text Add to dashboard Cite

Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lymphoma and novel targeted therapies, based on new bendamustine regimens/combinations, are being developed against CLL and lymphomas. In 2010, an international panel of bendamustine experts met and published a set of recommendations on the safe and effective use of bendamustine in patients suffering from hematologic disorders. In 2014, this panel met again to update these recommendations since the clarification of issues including optimal dosing and management of bendamustine-related toxicities. The aim of this report is to communicate the latest consensus on the use of bendamustine, permitting the expansion of its safe and effective administration, particularly in new combination therapies.

show abstract

Bendamustine is effective in T‐Cell prolymphocytic leukaemia

Cited by 37 publications

References 10 publications

Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review

Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review

T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib)

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update

Contact Info

Product

Resources

About